August 22, 2014 (www.investorideas.com newswire) There is considerable buzz out there that a large population of Baby Boomer generation is gearing up to sell its business endeavors to younger buyers. The forecast is that business-owning Boomers are ready to enter into their Golden Years and that in the next 20 years there will be trillions of dollars’ worth of businesses that go on the market as they do. Let’s say the prediction is true – are there enough prospective buyers willing to test the small business market and send Baby Boomers into their retirement?
There are plenty buyers and they are a diverse and young bunch, according to a 2013 report by Bizjournals.com. In a study of 2,000 buyers and sellers, the report showed that more than ever before, women and minorities are looking for business ownership opportunities. While the market is still male-dominated (comprising 81% of all buyers), women accounted for 9% of buyers over 65 years old; 19% of buyers 50-64 years old; 20% of buyers 30-49 years old, and 23% of buyers 18-29 years old.
Interested parties were also more racially diverse, especially among the younger crowd. Bizjournals.com reported findings that while 87% of buyers aged 65 and older were Caucasian, that percentage decreased as the age of buyers decreased. Caucasians accounted for 78% of buyers aged 50-64 years; 66% of those aged 30-49 years; and 48% of those aged 18-29 years.
So how exactly will this transfer of generational assets go down once the Boomers are ready to sell?
Historically, business sellers would only provide minimal or no financing to the buyer. These types of transactions were too large for most individuals to finance and too risky for banks, which took into consideration the company's individual merits as opposed to the buyer's personal balance sheet. On the other hand, these transactions were too small to interest most institutional investors.
Today, there's a new form of financing triggered by the anticipated Boomer sell-off.
Companies like LD Holdings are gearing up to step in and fill-in the blanks, noting that there are currently more than 25 million small businesses worth an aggregate $17 trillion that will be sold in the next 15-20 years. This particular company's goal is to become a "known buyer" of small companies that meet its acquisition criteria, including an existing management and personnel, brand equity, customers and cash flow, at discounted prices. It will then attempt to produce venture capital-type returns without the venture capital risks associated with a start-up company.
Within five years, LD Holdings plans to accumulate at least 45 of these small companies and to slowly meld them into cohesive business units. The company's objective, through aggressive use of the Internet, is that while the search for acquisitions is being conducted, it will establish an outside investor base that shares the company's vision and objectives is willing to hold their positions for a year or more.
Through its Business Services Division, LD Holdings maintains a database of entrepreneurs looking for business owning opportunities, giving particular attention to those with specific backgrounds and expertise that will be available for both acquisition evaluation and strategizing the post-acquisition business model, once the financial aspects of the transaction are determined.
For more information visit www.nutranomics.com
NutraNomics Inc. (NNRX) High Bioavailability Food and Plant Based Nutraceutical Product Quality Ahead of Curve in Growing Global Market
In a world where health is seemingly dominated by the synthetic pharmaceutical industry and where people also seem to be nevertheless getting sicker than ever, nutraceuticals have emerged as an alternative, nutrition-based approach to staving off the onset of debilitating conditions like high cholesterol, high blood pressure, and heart disease. The statistics of these three related issues alone speak volumes, with CDC data telling the tale of the tape, indicating that just under half of the 67M plus Americans (31%) with high blood pressure even have it under control and an even higher number, around 33.5% of the population, have high cholesterol. The heart disease data should come as little shock then, with an American dying every 33 seconds from cardiovascular disease and women now accounting for more than half the total number of fatalities, despite the prevalence of the myth that heart disease is somehow a man's disease.
Sure, the synthetic pharma route is wide and open to all comers, with statin drugs like Crestor or Lipitor readily available to savagely hammer LDL levels (low-density lipoprotein or so-called "bad" cholesterol). But, these drugs can also cause numerous side effects. In the case of statins, side effects range from muscle pain to damage of muscle and liver tissue. Depressed mental acuity and conditions like anemia, acidosis, cataracts, and frequent fevers, are also possible. Such potentially dangerous side effects (similar problems exist for heart disease and high blood pressure medications) are a considerable deterrent force which has pushed more and more consumers to seek out healthier alternatives, leading to a boom in nutraceuticals and specialized nutritional supplements, with obvious big-name international players like Herbalife Ltd. (NYSE:HLF), or NA-focused GNC Holdings, Inc. (NYSE:GNC), benefitting off the groundswell in terms of market capitalization.
But not all nutraceuticals are created equally and the vast majority of over the counter supplements simply are not formulated or engineered in such a way that the product is of real value nutritionally, often also containing harmful adulterants like the manufacturing flow agent, magnesium stearate (or similar binders/fillers), as is the case with most multivitamins you see in stores, even top name brands. NutraNomics® however, has devised an approach to formulating nutraceuticals using whole foods containing the key antioxidants, enzymes, fatty acids, phytonutrients (naturally-occurring chemical compounds often unique to a given plant species) and other proteins the body needs, using an advanced proprietary Glyco-Protein Matrix process involving humble brewer's yeast, which processes/readies the nutrients for maximum uptake by the body. Further enhancing their superior food and plant based products, which are derived from only high-quality, China-free, diligently sourced raw materials, NNRX employs their patented Assimilation Enhancing System® to greatly improve the product's overall bioavailability. Bioavailability of undamaged nutrients is key as the body is continually making new cells to replace old ones and simply cannot manufacture healthy new cells using damaged nutrients from dead food and/or synthetic chemicals, which it doesn't recognize and which are generally speaking "programmed" (pharmaceuticals) to exploit the body's operating system in some way.
NNRX has even devised comprehensive protocols focusing on their products combined with a healthy regimen (and/or dietary protocol) for a wide variety of conditions, including high cholesterol, high blood pressure, and heart disease, fully embracing the concept of public outreach to customers and education as being core to long-term profitability of the nutraceuticals business model. For a small company like NNRX which is focused squarely on delivering a superior product, it is striking that they nevertheless have established salesforce presence in an array of markets outside the U.S. and Canada. With a solid lead in the Philippines (where the company has a deal with one of the biggest health and natural product, direct and multi-level distributors, UNO International Corp.), Singapore and Malaysia, as well as Japan, Taiwan, Korea, and even Poland, NNRX is able to strike across the earth's surface with noticeable force for their size. Good news for NNRX investors, given the April 2014 report on the nutraceuticals sector out of Ken Research (Global Nutraceuticals Industry Analysis till 2017), which indicates that the Asia-Pacific and Latin American markets will be key growth areas in years to come. The company also has a considerable ecommerce presence, with products available on their site via the cart and now also available on ecommerce juggernaut Amazon.com, Inc. (NASDAQ:AMZN), as well as on the extremely popular health nutrition-focused portal RevNutrition.com, which has a large base of fiercely loyal users.
The Ken Research report on the nutraceuticals sector also targets global revenues to top out around $424B by just 2017, observing strong traction among consumers and a growing awareness of the compelling health/medicinal benefits of nutraceuticals, as well as their capacity in helping to prevent diseases, as strong drivers of the 8.2% CAGR seen for the period between 2006 and 2012. A recent report out of Micro Market Monitor focusing on the European minerals market, which is being buoyed by the nutraceutical boom, makes another strong case for NNRX being able to punch above its weight in a growing industry, projecting a 7.2% CAGR through 2018 in Europe, where consumers look to be spending more categorically on superior quality nutraceuticals. Micro Market Monitor sees the minerals market growing substantially in Europe in coming years, to around $845M plus by 2018, up sharply from the estimated $558M seen in 2012.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.